NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that it has formed a strategic partnership with Ascendas Genomics to develop molecular diagnostics in China.

Under the agreement, Ascendas will develop and commercialize molecular diagnostic systems and assays using microfluidic technologies included in Fluidigm's Biomark HD and Juno systems.

Fluidigm's platforms enable scalable and automated workflows for quantitative PCR, gene expression, copy number variation analysis, and next-generation sequencing library preparation.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Feb
27

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep. 

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.